Lupus and T Cells

Lupus

Volumn 18, Issue 3, 2009, Pages 196-201

  La Cava, Antonio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anti DNA antibodies; Nephritis; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; B7 ANTIGEN; CD137 ANTIGEN; CD28 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TOLL LIKE RECEPTOR;

ANTIGEN PRESENTING CELL; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TARGET CELL; THROMBOEMBOLISM;

ANIMALS; AUTOANTIBODIES; HOMEOSTASIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 60449114822     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308098191     Document Type: Review

References (69)

1. Arbuckle MR, McClain MT, Rubertone MV. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533.
2. Datta SK, Patel H, Berry D. Induction of a cationic shift in IgG anti-DNA autoantibodies. Role of T helper cells with classical and novel phenotypes in three murine models of lupus nephritis. J Exp Med 1987; 165: 1252-1268.
3. Santoro TJ, Portanova JP, Kotzin BL. The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRLlpr/lpr mice. J Exp Med 1988; 167: 1713-1718.
4. Singh RR, Dubey S. Autoantigens and defects in immune tolerance in lupus. In: DJ, Wallace BH, Hahn (eds), Dubois Lupus Erythematosus. 7th ed. Philadelphia: Lippincott William & Wilkins; 2007. p. 370-406.
5. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987; 138: 3247-3253.
6. Mihara M, Ohsugi Y, Saito K. Immunologic abnormality in NZB/NZW F1 mice. Thymus-independent occurrence of B cell abnormality and requirement for T cells in the development of autoimmune disease, as evidenced by an analysis of the athymic nude individuals. J Immunol 1988; 141: 85-90.
7. Messner RP, Lindström FD, Williams RC. Peripheral blood lymphocyte cell surface markers during the course of systemic lupus erythematosus. J Clin Invest 1973; 52: 3046-3056.
8. Glinski W, Gershwin ME, Steinberg AD. Fractionation of cells on a discontinuous Ficoll gradient. Study of subpopulations of human T cells using anti-T-cell antibodies from patients with systemic lupus erythematosus. J Clin Invest 1976; 57: 604-614.
9. Rivero SJ, Llorente L, Díaz-Jouanen E, Alarcón-Segovia D. T-lymphocyte subpopulation in untreated SLE. Variations with disease activity. Arthritis Rheum 1977; 20: 1169-1173.
10. Rivero SJ, Díaz-Jouanen E, Alarcón-Segovia D. Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. Arthritis Rheum 1978; 21: 295-305.
11. Bakke AC, Kirkland PA, Kitridou RC. T lymphocyte subsets in systemic lupus erythematosus. Correlations with corticosteroid therapy and disease activity. Arthritis Rheum 1983; 26: 745-750.
12. Wither J, Vukusic B. Autoimmunity develops in lupus-prone NZB mice despite normal T cell tolerance. J Immunol 1998; 161: 4555-4562.
13. Fatenejad S, Peng SL, Disorbo O, Craft J. Central T cell tolerance in lupus-prone mice: Influence of autoimmune background and the lpr mutation. J Immunol 1998; 161: 6427-6432.
14. Xu L, Zhang L, Yi Y, Kang HK, Datta SK. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 2004; 10: 411-415.
15. Budagyan VM, Bulanova EG, Sharova NI, Nikonova MF, Stanislav ML, Yarylin AA. The resistance of activated T-cells from SLE patients to apoptosis induced by human thymic stromal cells. Immunol Lett 1998; 60: 1-5.
16. Horwitz DA, Gray JD. The interaction of T cells with cells of the innate immune system and B cells in the pathogenesis of SLE. In: DJ Wallace, BH Hahn, (eds), Dubois' lupus erythematosus. 6th ed. Philadelphia: Lippincott William & Wilkins; 2002 p. 133-160.
17. La Cava A. T-regulatory cells in systemic lupus erythematosus. Lupus 2008; 17: 421-425.
18. Murashima A, Takasaki Y, Ohgaki M, Hashimoto H, Shirai T, Hirose S. Activated peripheral blood mononuclear cells detected by murine monoclonal antibodies to proliferating cell nuclear antigen in active lupus patients. J Clin Immunol 1990; 10: 28-37.
19. Dawisha SM, Gmelig-Meyling F, Steinberg AD. Assessment of clinical parameters associated with increased frequency of mutant T cells in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 270-277.
20. Campen DH, Horwitz DA, Quismorio FP, Ehresmann GR, Martin WJ. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum 1988; 31: 1358-1364.
21. Samsonov MY, Tilz GP, Egorova O. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4: 29-32.
22. Aderka D, Wysenbeek A, Engelmann H. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1111-1120.
23. Okudaira K, Searles RP, Goodwin JS, Williams RC. Antibodies in the sera of patients with systemic lupus erythematosus that block the binding of monoclonal anti-Ia to Ia-positive targets also inhibit the autologous mixed lymphocyte response. J Immunol 1982; 129: 582-586.
24. Yamada A, Shaw M, Winfield JB. Surface antigen specificity of cold-reactive IgM antilymphocyte antibodies in systemic lupus erythematosus. Arthritis Rheum 1985; 28: 44-51.
25. Wernet P, Kunkel HG. Antibodies to a specific surface antigen of T cells in human sera inhibiting mixed leukocyte culture reactions. J Exp Med 1973; 138: 1021-1026.
26. Hahn BH, Pletscher LS, Muniain M, MacDermott RP. Suppression of the normal autologous mixed leukocyte reaction by sera from patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25: 381-389.
27. Charpentier B, Carnaud C, Bach JF. Selective depression of the xenogeneic cell-mediated lympholysis in systemic lupus erythematosus. J Clin Invest 1979; 64: 351-360.
28. Raziuddin S, Nur MA, Al-Wabel AA. Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: Alterations associated with prednisolone therapy. Scand J Immunol 1990; 31: 139-145.
29. Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol 1995; 155: 2269-2281.
30. Blasini AM, Alonzo E, Chacón R, Riera R, Stekman IL, Rodriguez MA. Abnormal pattern of tyrosine phosphorylation in unstimulated peripheral blood T lymphocytes from patients with systemic lupus erythematosus. Lupus 1998; 7: 515-523.
31. Kammer GM, Laxminarayana D, Khan IU. Mechanisms of deficient type I protein kinase a activity in lupus T lymphocytes. Int Rev Immunol 2004; 23: 225-244.
32. Takeuchi T, Pang M, Amano K, Koide J, Abe T. Reduced protein tyrosine phosphatase (PTPase) activity of CD45 on peripheral blood lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1997; 109: 20-26.
33. Jury E, Kabouridis PS, Abba A, Mageed RA, Isenberg DA. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1343-1354.
34. Yi Y, McNerney M, Datta SK. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2000; 165: 6627-6634.
35. Tenbrock K, Juang YT, Tolnay M, Tsokos GC. The cyclic adenosine 5′-monophosphate response element modulator suppresses IL-2 production in stimulated T cells by a chromatin-dependent mechanism. J Immunol 2003; 170: 2971-2976.
36. Sierakowski S, Kucharz EJ, Lightfoot RW, Goodwin JS. Impaired T-cell activation in patients with systemic lupus erythematosus. J Clin Immunol 1989; 9: 469-476.
37. Perl A, Nagy G, Gergely P, Puskas F, Qian Y, Banki K. Apoptosis and mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. Methods Mol Med 2004; 102: 87-114.
38. Juang YT, Wang Y, Solomou EE. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005; 115: 996-1005.
39. Dauphinée MJ, Kipper SB, Wofsy D, Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol 1981; 127: 2483-2487.
40. Altman A, Theofilopoulos AN, Weiner R, Katz DH, Dixon FJ. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med 1981; 154: 791-808.
41. Wofsy D, Murphy ED, Roths JB, Dauphinée MJ, Kipper SB, Talal N. Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene. J Exp Med 1981; 154: 1671-1680.
42. Alcocer-Varela J, Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982; 69: 1388-1392.
43. Linker-Israeli M, Bakke AC, Kitridou RC, Gendler S, Gillis S, Horwitz DA. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983; 130: 2651-2655.
44. Tsokos GC, Nambiar MP, Tenbrock K, Juang YT. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 2003; 24: 259-263.
45. Cedeño S, Cifarelli DF, Blasini AM. Defective activity of ERK-1 and ERK-2 mitogen-activated protein kinases in peripheral blood T lymphocytes from patients with systemic lupus erythematosus: Potential role of altered coupling of Ras guanine nucleotide exchange factor hSos to adapter protein Grb2 in lupus T cells. Clin Immunol 2003; 106: 41-49.
46. Katsiari CG, Kyttaris VC, Juang YT, Tsokos GC. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest 2005; 115: 3193-3204.
47. Jury EC, Kabouridis PS. T-lymphocyte signalling in systemic lupus erythematosus: A lipid raft perspective. Lupus 2004; 13: 413-422.
48. Krishnan S, Nambiar MP, Warke VG. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 2004; 172: 7821-7831.
49. Jury EC, Kabouridis PS, Abba A, Mageed RA, Isenberg DA. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48: 1343-1354.
50. Jury EC, Kabouridis PS, Flores-Borja F, Mageed RA, Isenberg DA. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 2004; 113: 1176-1187.
51. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRLlpr/lpr mouse. J Clin Invest 2003; 111: 539-552.
52. Singh RP, Hahn BH, La Cava A. Tuning immune suppression in systemic autoimmunity with self-derived peptides. (http://www.ncbi.nlm.nih.gov/ pubmed/19075790?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed. Pubmed_DefaultReportPanel.Pubmed_RVDocSum). Inflamm Allergy Drug Targets 2008; 7: 253-259.
53. Mauermann N, Sthoeger Z, Zinger H, Mozes E. Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 2004; 137: 513-520.
54. Luger D, Dayan M, Zinger H, Liu J, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004; 24: 579-590.
55. Ramanujam M, Wang X, Huang W. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004; 173: 3524-3534.
56. Ferrera F, Filaci G, Rizzi M. New therapies in SLE. Recents Patents Inflamm Allergy Drug Discov 2008;2: 11-23.
57. Mohan C, Shi Y, Laman J, Datta S. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 1470-1480.
58. Koshy M, Berger D, Crow M. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826-837.
59. Yellin M, D'Agati V, Parkinson G. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997; 40: 124-134.
60. Wang X, Huang W, Schiffer L. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 2003; 48: 495-506.
61. Huang W, Sinha J, Newman J. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1554-1562.
62. Davis JJ, Totoritis M, Rosenberg J, Sklenar T, Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95-101.
63. Kalunian K, Davis JJ, Merrill J, Totoritis M, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 3251-3258.
64. Boumpas D, Furie R, Manzi S. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003; 48: 719-727.
65. McAdam A, Greenwald R, Levin M. ICOS is critical for CD40-mediated antibody class switching. Nature 2001; 409: 102-105.
66. Iwai H, Abe M, Hirose S. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol 2003; 171: 2848-2854.
67. Sun Y, Subudhi S, Fu Y. Co-stimulation agonists as a new immunotherapy for autoimmune diseases. Trends Mol Med 2003; 9: 483-489.
68. Sun Y, Chen H, Subudhi S. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 2002; 8: 1405-1413.
69. Mittler R, Foell J, McCausland M. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer. Immunol Res 2004; 29: 197-208.